All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
BTK inhibitors
BTK inhibitors
Bruton Tyrosine Kinase (BTK) inhibitors inhibit the enzyme BTK, which plays a crucial role in oncogenic signaling and interactions with tumour microenvironment, critical for proliferation and survival of malignant B cells. Examples of BTK inhibitors include ibrutinib, zanubrutinib, and acalabrutinib.